Sarepta Therapeutics Securities Lawsuit: Investors Advised to Act Before Deadline

Sarepta Therapeutics shareholders who purchased securities between June 22, 2023, and June 24, 2025, have until August 25, 2025, to contact DJS Law Group about a class action lawsuit alleging the company made false and misleading statements about its ELEVIDYS therapy and revenue outlook. The firm specializes in securities class actions and corporate governance litigation.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is the subject of a class action lawsuit alleging federal securities violations, according to recent notices from legal firms. The lawsuit, captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), alleges that the company made false and/or misleading statements and failed to disclose significant risks associated with its ELEVIDYS therapy [1].

The class period for the lawsuit is from June 22, 2023, to June 24, 2025. The complaint alleges that during this period, Sarepta issued materially false and/or misleading statements and/or failed to disclose that ELEVIDYS posed significant safety risks to patients, that trial regimes and protocols failed to detect severe side effects, and that the severity of adverse events would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals [2].

Investors who purchased shares of SRPT during the class period are encouraged to contact the Gross Law Firm by August 25, 2025, to discuss their rights. The Gross Law Firm, a nationally recognized class action law firm, seeks to protect the rights of investors who have suffered as a result of deceit, fraud, and illegal business practices [1].

The Rosen Law Firm also reminds investors that they may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The firm encourages investors to select qualified counsel with a track record of success in leadership roles [3].

Sarepta Therapeutics has not yet responded to the allegations in the lawsuit. The company has not released any official statements regarding the class action lawsuit.

References:
[1] https://www.globenewswire.com/news-release/2025/07/10/3113721/0/en/Sarepta-Therapeutics-Inc-Securities-Fraud-Class-Action-Lawsuit-Pending-Contact-The-Gross-Law-Firm-Before-August-25-2025-to-Discuss-Your-Rights-SRPT.html
[2] https://www.prnewswire.com/news-releases/srpt-investor-alert-robbins-geller-rudman--dowd-llp-announces-that-sarepta-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit-302503612.html
[3] https://www.prnewswire.com/news-releases/srpt-investors-have-opportunity-to-lead-sarepta-therapeutics-inc-securities-fraud-lawsuit-302503549.html